Abstract
Despite frequent KRAS mutation, the early molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) development have not been fully elucidated. By tracking a potential regulator of another feature of PDAC precursors, acquisition of foregut or gastric epithelial gene signature, we herein report that aberrant overexpression of ecotropic viral integration site 1 (EVI1) oncoprotein, which is usually absent in normal pancreatic duct, is a widespread marker across the full spectrum of human PDAC precursors and PDAC. In pancreatic cancer cells, EVI1 depletion caused remarkable inhibition of cell growth and migration, indicating its oncogenic roles. Importantly, we found that EVI1 upregulated KRAS expression through suppression of a potent KRAS suppressor, miR-96, in pancreatic cancer cells. Collectively, the present findings suggest that EVI1 overexpression and KRAS mutation converge on activation of the KRAS pathway in early phases of pancreatic carcinogenesis and propose EVI1 and/or miR-96 as early markers and therapeutic targets in this dismal disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Hruban R, Boffetta P, Hiraoka N, Iacobuzio-Donahue C, Kato Y, Kern S et al. Tumours of the pancreas. In: Bosman F, Carneiro F, Hruban R, Theise N eds). WHO Classification of Tumours of the Digestive System 4th edn International Agency for Research on Cancer (IARC), Lyon, 2010, pp 279–337.
Prasad NB, Biankin AV, Fukushima N, Maitra A, Dhara S, Elkahloun AG et al. Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res 2005; 65: 1619–1626.
Kim GE, Bae HI, Park HU, Kuan SF, Crawley SC, Ho JJ et al. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002; 123: 1052–1060.
Yonezawa S, Higashi M, Yamada N, Yokoyama S, Goto M . Significance of mucin expression in pancreatobiliary neoplasms. J Hepatobiliary Pancreat Sci 2010; 17: 108–124.
Tanaka M, Shibahara J, Fukushima N, Shinozaki A, Umeda M, Ishikawa S et al. Claudin-18 is an early-stage marker of pancreatic carcinogenesis. J Histochem Cytochem 2011; 59: 942–952.
Morris JPt, Wang SC, Hebrok M . KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010; 10: 683–695.
Hruban R, Pitman M, Klimstra D . Tuomrs of the pancreas. In: Silverberg S (ed). AFIP Atlas of Tumor Pathology. American Registry of Pathology, Washington DC, 2007, pp 51–164.
Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111–120.
Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003; 4: 437–450.
De La OJ, Emerson LL, Goodman JL, Froebe SC, Illum BE, Curtis AB et al. Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA 2008; 105: 18907–18912.
Goyama S, Kurokawa M . Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009; 100: 990–995.
Yoshimi A, Kurokawa M . Evi1 forms a bridge between the epigenetic machinery and signaling pathways. Oncotarget 2011; 2: 575–586.
Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005; 86: 127–141.
Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 2005; 21: 2933–2942.
Quandt K, Frech K, Karas H, Wingender E, Werner T . MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acids Res 1995; 23: 4878–4884.
Song Y, Washington MK, Crawford HC . Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 2010; 70: 2115–2125.
Kwei KA, Bashyam MD, Kao J, Ratheesh R, Reddy EC, Kim YH et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet 2008; 4: e1000081.
Izutsu K, Kurokawa M, Imai Y, Maki K, Mitani K, Hirai H . The corepressor CtBP interacts with Evi-1 to repress transforming growth factor beta signaling. Blood 2001; 97: 2815–2822.
Kurokawa M, Mitani K, Irie K, Matsuyama T, Takahashi T, Chiba S et al. The oncoprotein Evi-1 represses TGF-beta signalling by inhibiting Smad3. Nature 1998; 394: 92–96.
Kurokawa M, Mitani K, Yamagata T, Takahashi T, Izutsu K, Ogawa S et al. The evi-1 oncoprotein inhibits c-Jun N-terminal kinase and prevents stress-induced cell death. EMBO J 2000; 19: 2958–2968.
Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E et al. Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 2011; 117: 3617–3628.
Liu Y, Chen L, Ko TC, Fields AP, Thompson EA . Evi1 is a survival factor which conveys resistance to both TGFbeta- and taxol-mediated cell death via PI3K/AKT. Oncogene 2006; 25: 3565–3575.
Gysin S, Lee SH, Dean NM, McMahon M . Pharmacologic inhibition of RAF–;>MEK–;>ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1. Canceer Res 2005; 65: 4870–4880.
Suzuki HI, Miyazono K . Dynamics of microRNA biogenesis: crosstalk between p53 network and microRNA processing pathway. J Mol Med (Berl) 2010; 88: 1085–1094.
Suzuki HI, Miyazono K . Emerging complexity of microRNA generation cascades. J Biochem 2011; 149: 15–25.
Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K . Modulation of microRNA processing by p53. Nature 2009; 460: 529–533.
Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH . miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011; 404: 896–902.
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene 2009; 28: 1385–1392.
Gao JS, Zhang Y, Tang X, Tucker LD, Tarwater PM, Quesenberry PJ et al. The Evi1, microRNA-143, K-Ras axis in colon cancer. FEBS Lett 2011; 585: 693–699.
Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007; 26: 4442–4452.
Gomez-Benito M, Conchillo A, Garcia MA, Vazquez I, Maicas M, Vicente C et al. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2. Br J Cancer 2010; 103: 1292–1296.
De Weer A, Van der Meulen J, Rondou P, Taghon T, Konrad TA, De Preter K et al. EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells. Br J Haematol 2011; 154: 337–348.
Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG et al. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol 2010; 24: 447–463.
Senyuk V, Premanand K, Xu P, Qian Z, Nucifora G . The oncoprotein EVI1 and the DNA methyltransferase Dnmt3 co-operate in binding and de novo methylation of target DNA. PLoS One 2011; 6: e20793.
Dickstein J, Senyuk V, Premanand K, Laricchia-Robbio L, Xu P, Cattaneo F et al. Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 2010; 107: 9783–9788.
Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70: 6015–6025.
Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17: 500–503.
Nanjundan M, Nakayama Y, Cheng KW, Lahad J, Liu J, Lu K et al. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer. Cancer Res 2007; 67: 3074–3084.
Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N et al. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 2011; 96: 1448–1456.
Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology 2012; 142: 730–733 e739.
Logsdon CD, Ji B . Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7: S40–S43.
Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology 2009; 137: 1072–1082 1082 e1-6.
Kitago M, Ueda M, Aiura K, Suzuki K, Hoshimoto S, Takahashi S et al. Comparison of K-ras point mutation distributions in intraductal papillary-mucinous tumors and ductal adenocarcinoma of the pancreas. Int J Cancer 2004; 110: 177–182.
Jimenez RE, Warshaw AL, Z’Graggen K, Hartwig W, Taylor DZ, Compton CC et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg 1999; 230: 501–509 discussion 509-511.
Matsuyama H, Suzuki HI, Nishimori H, Noguchi M, Yao T, Komatsu N et al. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma. Blood 2011; 118: 6881–6892.
Sentani K, Oue N, Tashiro T, Sakamoto N, Nishisaka T, Fukuhara Tea . Immunohistochemical staining of Reg IV and claudin-18 is useful in the diagnosis of gastrointestinal signet ring cell carcinoma. Am J Surg Pathol 2008; 32: 1182–1189.
Acknowledgements
We thank all members of the Department of Pathology, University of Tokyo. This work was supported by the Industrial Technology Research Grant Program (2008) from the New Energy and Industrial Technology Development Organization (NEDO) of Japan (SI), the Grant-in-Aid for Scientific Research on Innovative Areas (SI),46 the Grant-in-Aid for Young Scientists (A),46 the GCOE Program for ‘Integrative Life Science Based on the Study of Biosignaling Mechanisms’ (HIS, KM), and for ‘Chemical Biology of the Diseases’ (MF and MK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Cell Science Research Foundation (HIS, KM).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Oncogene website
Rights and permissions
About this article
Cite this article
Tanaka, M., Suzuki, H., Shibahara, J. et al. EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis. Oncogene 33, 2454–2463 (2014). https://doi.org/10.1038/onc.2013.204
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.204
Keywords
This article is cited by
-
Pancreatic Cancer: Genetic Conditions and Epigenetic Alterations
Journal of Gastrointestinal Surgery (2023)
-
Emerging role of non-coding RNAs in the regulation of KRAS
Cancer Cell International (2022)
-
MECOM permits pancreatic acinar cell dedifferentiation avoiding cell death under stress conditions
Cell Death & Differentiation (2021)
-
PRDM3 attenuates pancreatitis and pancreatic tumorigenesis by regulating inflammatory response
Cell Death & Disease (2020)
-
EVI1 promotes epithelial-to-mesenchymal transition, cancer stem cell features and chemo−/radioresistance in nasopharyngeal carcinoma
Journal of Experimental & Clinical Cancer Research (2019)